Delix Therapeutics has raised $70 million in series A financing to develop therapies inspired by psychedelics to treat neuropsychiatric and neurodegenerative diseases. The Boston-based start-up joins a list of more than a dozen drug companies developing psychedelic-based therapies for mental illnesses. CEO Mark Rus says Delix is part of a “psychedelic renais...
Our hominin ancestors inevitably encountered and likely ingested psychedelic mushrooms throughout their evolutionary history. This assertion is supported by current understanding of: early hominins' paleodiet and paleoecology; primate phylogeny of mycophagical and self-medicative behaviors; and the biogeography of psilocybin-containing fungi. These lines of ...
As both 3,4-methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted psychedelic psychotherapy near U.S. Food and Drug Administration (FDA) approval and gain acceptance as efficacious clinical approaches, concerns have been raised about the likelihood of sexual violation of a client and other relational boundary transgressions. In the current study, 23 ...
The publication in April 2021 of the Imperial College London Phase II study investigating \nthe efficacy of psilocybin-assisted therapy vs. escitalopram for depression reported differences \nin the primary outcome measure (the QIDS-SR16) between experimental and control arms as \nstatistically insignificant (1). However, secondary measures of dep...
Spontaneous Spiritual Awakenings (SSAs) are subjective experiences characterised by a sudden sense of direct contact, union, or complete nondual merging (experience of oneness) with a perceived ultimate reality, the universe, "God," or the divine. These profound transformative experiences have scarcely been researched, despite extensive anecdotal evidence su...
The therapeutic use of psilocybin in psychedelic-assisted therapy models is currently being tested for a variety of indications, necessitating the training of hundreds of therapists. At present, training programs do not include the provision of a psilocybin experience for therapists, and the last time such an experience was offered with a similar compound wa...
The primary objective of this qualitative study was to explore the therapeutic trajectories of individuals undergoing psilocybin-assisted group therapy. This interpretive phenomenological analysis focused on an enriched study sample of gay-identified cisgender men ( n = 9) with human immunodeficiency virus diagnosed before 1996 and clinically significant tra...
Spontaneous Spiritual Awakenings (SSAs) are subjective experiences characterised by a sud- den sense of direct contact, union or merging with a perceived ultimate reality, the universe, or the divine. These profound transformative experiences have scarcely been researched, de- spite extensive anecdotal evidence suggesting their potential to catalyse drastic,...
Objective: Recent clinical trials have demonstrated that psilocybin may have strong antidepressant effects, and may be effective in the treatment of depressive disorders when embedded in a psychotherapeutic protocol (psilocybin-assisted psychotherapy; PAP). However, despite promising results, the mechanism(s) that may be responsible for the antidepressant ef...
Psychedelic therapies intentionally combine a caring/healing environment, psychotherapy, and psychedelic medicine as a powerful means of treating intractable conditions of depression and posttraumatic stress disorder. This article utilizes the nursing theory of human caring science, as articulated by Jean Watson, to describe the essential and fundamental hum...
Depression and post-traumatic stress disorder (PTSD), in the past two decades, has been a growing problem among adults and our youth. For hundreds, if not thousands of years, plant-based psychedelic drugs, such as psilocybin and peyote, have been utilized for medical purposes by numerous native tribal people As early as 1950, lysergic acid diethylamide (LSD)...
Despite a politically vilified past, classical psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), are experiencing a revival in scientific and clinical research. When used under the appropriate guidance and setting, these substances show promise for substantially improving well-being and reducing mental ill-he...
ObjectiveResearch into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical-type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long-term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight streng...
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear...
‘Why is psychedelic culture dominated by privileged white men?’ asks historian Mike Jay, referring to a recent study of psychedelic users who are more than likely to be college-educated white males.1 This appears logical, given the figureheads (such as Timothy Leary) who attained cult-like status half a century ago. Many today continue to view psychedelics a...
Psychedelics are back in vogue. In popular culture, political legislation, and scientific research, we appear to be witnessing an early twenty-first century renaissance of the heady acid days of the 1960s. The success of Michael Pollan’s 2018 New York Times bestseller, How to Change Your Mind, the decriminalization of psilocybin-containing mushrooms in Denve...
Machine Learning is used to predict the efficacy of psilocybin in treating mental health and addiction by using a random forest algorithm. Psilocybin is a chemical compound found in fungi. Following ingestion, it is converted to psilocin which acts as a serotonin agonist, producing altered states of consciousness and hallucinations. Research suggests the use...
Mental illnesses, especially depression, are a global problem that require new treatment options to those whose symptoms are resistant to the current ones. Psilocybin, which is a naturally occurring drug in mushrooms, has become a potential candidate. It affects the brain by deactivating certain areas, causing not only changes in perception and consciousness...
OBJECTIVE: The number of novel psychedelic phenethylamines and tryptamines has continued to increase, but little academic research has focused on the effects of these substances. We sought to determine and compare the subjective effects of various substances. METHODS: We conducted in-depth interviews with 39 adults (75.4% male and 87.2% White) who reported e...
